Zacks Investment Research Downgrades Miragen Therapeutics (MGEN) to Hold
Miragen Therapeutics (NASDAQ:MGEN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.
According to Zacks, “Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. “
A number of other research analysts also recently weighed in on MGEN. B. Riley began coverage on shares of Miragen Therapeutics in a research report on Friday. They issued a “buy” rating and a $15.50 target price for the company. Chardan Capital reaffirmed a “buy” rating and issued a $29.00 target price on shares of Miragen Therapeutics in a research report on Monday, October 16th. Finally, Wedbush reaffirmed a “buy” rating and issued a $19.00 target price on shares of Miragen Therapeutics in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $17.88.
Miragen Therapeutics (NASDAQ:MGEN) last issued its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.12. Miragen Therapeutics had a negative net margin of 720.38% and a negative return on equity of 80.31%. The company had revenue of $1.63 million during the quarter, compared to the consensus estimate of $0.72 million. research analysts expect that Miragen Therapeutics will post -1.39 EPS for the current fiscal year.
In related news, Director Thomas E. Hughes sold 12,000 shares of the firm’s stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $8.00, for a total value of $96,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 44.40% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in MGEN. Seaward Management Limited Partnership acquired a new stake in Miragen Therapeutics in the third quarter valued at $117,000. Russell Investments Group Ltd. acquired a new stake in Miragen Therapeutics in the third quarter valued at $147,000. BSW Wealth Partners acquired a new stake in Miragen Therapeutics in the third quarter valued at $203,000. Finally, SG Americas Securities LLC acquired a new stake in Miragen Therapeutics in the third quarter valued at $250,000. 22.64% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Downgrades Miragen Therapeutics (MGEN) to Hold” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/06/zacks-investment-research-downgrades-miragen-therapeutics-mgen-to-hold.html.
Miragen Therapeutics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.